Jointown Pharmaceutical Group Co., Ltd. was founded in 1985 at the beginning of reformation and opening up. It is a joint-stock enterprise with western medicine, Chinese medicine and medical equipment wholesale, logistics distribution, retail chain and e-commerce as its core business.
-
Year 2009
The company’s tax-included sales statistical indicator was 22 Billion RMB. It was the largest private enterprise in China Hubei Province, ranking third among nearly 10,000 pharmaceutical commercial enterprises in the country, and first among Chinese private pharmaceutical commercial enterprises. It had been shortlisted for 6 consecutive years in the “China “Top 500 Enterprises”. As of 2009, the company had total assets of more than 7 Billion RMB, and more than 380 subsidiaries.
-
November 2nd, 2010
Listed on the Shanghai Stock Exchange. (Stock abbreviation: “JOINTOWN”, stock code: 600998)
-
July 2020
Jointown Pharmaceutical Group ranked 100th in the 2020 Fortune China 500 list.
-
September 10th, 2020
The 2020 China Top 500 Private Enterprises List was released, and Jointown Pharmaceutical Group Co., Ltd. ranked 58th.
-
December 2021
Jointown Pharmaceutical Group ranked 93th in the 2021 Fortune China 500 list.
-
April 2022
Jointown released the 2021 annual report and the 2022 first quarter report. Under the disturbance of the epidemic, its performance still reached a new high. In 2021, the turnover of Jointown has reached 122.407 billion RMB, a year-on-year increase of 10.42%.
-
December 2022
Jointown Pharmaceutical Group ranked 68th in the 2022 Fortune China 500 list.
-
April 2023
In 2023, the turnover of Jointown kept increasing to 140.424 billion RMB.
-
December 2023
Jointown Pharmaceutical Group ranked 57th in the 2023 Fortune China 500 list.
-
April 2024
In 2024, the turnover of Jointown kept increasing to 150.14 billion RMB.
Milestones of Jointown
Finalist in China
500
Private Chinese pharmaceutical companies
Ranked 1st
2023 turnover
150.14 Billion RMB
Total connection to China Medical Channels
Enterprise-scale landing｜Pharmaceutical channel｜Cross-border e-commerce｜Integrated marketing
